SOPHiA GENETICS

SOPHiA GENETICS EBIT

The EBIT of SOPHiA GENETICS (SOPH) as of Nov 9, 2026 is -75.81 M USD. In the previous year, EBIT was -66.57 M USD — a change of 13.88% (lower).

EBIT

-75.81 MUSD

YoY

13.88%

Last updated:

In 2025, SOPHiA GENETICS's EBIT was -75.81 M USD, a 13.88% increase from the -66.57 M USD EBIT recorded in the previous year.

The SOPHiA GENETICS EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT
Date
EBIT
Jan 1, 2023
-74.83 M USD
Jan 1, 2024
-66.57 M USD
Jan 1, 2025
-75.81 M USD
Jan 1, 2026 (e)
-62.30 M USD
Jan 1, 2027 (e)
-38.45 M USD
Jan 1, 2028 (e)
-14.38 M USD
Jan 1, 2029 (e)
1.90 M USD
Jan 1, 2030 (e)
47.66 M USD
The SOPHiA GENETICS EBIT history
YEAREBITYoY
est47.66 MUSD+2,406.77%
est1.90 MUSD-113.23%
est-14.38 MUSD-62.62%
est-38.45 MUSD-38.28%
est-62.30 MUSD-17.82%
-75.81 MUSD+13.88%
-66.57 MUSD-11.04%
-74.83 MUSD-14.80%
-87.82 MUSD+20.52%
-72.87 MUSD+80.44%
-40.39 MUSD+23.35%
-32.74 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

SOPHiA GENETICS Revenue

SOPHiA GENETICS Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
61.78 M USD
-74.83 M USD
-78.98 M USD
Jan 1, 2024
63.26 M USD
-66.57 M USD
-62.49 M USD
Jan 1, 2025
72.72 M USD
-75.81 M USD
-79.00 M USD
Jan 1, 2026 (e)
95.40 M USD
-62.30 M USD
-62.15 M USD
Jan 1, 2027 (e)
118.15 M USD
-38.45 M USD
-40.44 M USD
Jan 1, 2028 (e)
150.78 M USD
-14.38 M USD
-22.56 M USD
Jan 1, 2029 (e)
194.54 M USD
1.90 M USD
-452,355.92 USD
Jan 1, 2030 (e)
259.03 M USD
47.66 M USD
35.96 M USD

SOPHiA GENETICS Margins

SOPHiA GENETICS stock margins

The SOPHiA GENETICS margin analysis displays the gross margin, EBIT margin, as well as the profit margin of SOPHiA GENETICS. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for SOPHiA GENETICS.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2023
69.46 %
-121.11 %
-127.84 %
Jan 1, 2024
69.45 %
-105.23 %
-98.79 %
Jan 1, 2025
65.75 %
-104.25 %
-108.64 %
Jan 1, 2026 (e)
65.75 %
-65.30 %
-65.15 %
Jan 1, 2027 (e)
65.75 %
-32.55 %
-34.23 %
Jan 1, 2028 (e)
65.75 %
-9.53 %
-14.96 %
Jan 1, 2029 (e)
65.75 %
0.98 %
-0.23 %
Jan 1, 2030 (e)
65.75 %
18.40 %
13.88 %

SOPHiA GENETICS Stock analysis

What does SOPHiA GENETICS do? Sophia Genetics SA is a Swiss company that was founded in 2011. The idea behind it was to improve genome sequencing and data analysis in order to make faster and more precise medical diagnoses. Sophia Genetics has since become a leading provider of artificial intelligence and data analysis in the medical field. The business model of Sophia Genetics is based on providing doctors and medical facilities with corresponding data analysis tools and platforms. Sophia Genetics' algorithms help to identify genetic anomalies and develop personalized therapies. This personalized medicine aims to improve healthcare. Sophia Genetics is divided into various sectors. The core sectors include oncology, pediatrics, cardiology, and neurology. In these specialized fields, Sophia Genetics' platforms and tools are used to optimize genome sequencing and data analysis, thus enabling faster and more precise diagnoses. The company offers a variety of products that help doctors and medical facilities create successful diagnoses and therapies. Sophia Genetics' flagship product is the Sophia Artificial Intelligence (AI) platform. This platform is used by doctors, clinics, and research institutions to analyze complex data and identify the genetic causes of diseases. The Sophia AI platform provides fast, precise, and secure genome sequencing and data analysis. Sophia Genetics also offers the Sophia DDM system. The DDM system is a cloud-based data exchange system that provides doctors and medical facilities with a secure way to exchange confidential medical data. The system also allows for the collection and analysis of information about diseases and disease progression in the population, in order to enable better healthcare. Another important product of Sophia Genetics is the Sophia Hereditary Cancer Solution. This product helps in the early detection of hereditary cancer. The Sophia Hereditary Cancer Solution provides fast and precise genetic diagnostics to identify family members at increased risk of cancer and take appropriate measures. Another product of Sophia Genetics is Sophia Radiomics. This software uses artificial intelligence and machine learning to detect and characterize diseases based on X-ray and CT scans. By analyzing large amounts of data, the Sophia Radiomics software can assist doctors in making more precise diagnoses and better treatment decisions. Sophia Genetics relies on close collaboration with medical facilities and research institutions worldwide. The company now has customers in over 60 countries and is a partner to more than 1,000 hospitals worldwide. Sophia Genetics' platforms and tools have already helped many people to be diagnosed and treated faster and more accurately. Overall, Sophia Genetics is an innovative company that has revolutionized medical diagnostics. With its advanced platforms and tools, the company provides doctors and medical facilities with an excellent opportunity to develop personalized therapies and enable better healthcare. SOPHiA GENETICS is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing SOPHiA GENETICS's EBIT

SOPHiA GENETICS's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of SOPHiA GENETICS's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

SOPHiA GENETICS's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in SOPHiA GENETICS’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about SOPHiA GENETICS stock

EBIT of SOPHiA GENETICS is -75.81 M USD in 2025.

EBIT of SOPHiA GENETICS changed from -66.57 M USD to -75.81 M USD, representing a 13.88% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT SOPHiA GENETICS since 2006 – with annual values, charts, and detailed analysis.

"Earnings before interest and taxes", abbreviated as EBIT, is also referred to as the operating result of a company. It is a key figure that allows the profit to be assessed over a specific period of time, usually a fiscal year. Taxes and interest are not deducted from EBIT, making it suitable for international comparisons of different companies.

Net income
+ Tax expense
+ Interest expense and other financial expenses
- Interest income and other financial income
= EBIT (operating profit)

EBIT's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT's SOPHiA GENETICS historically and in real time.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — SOPHiA GENETICS

All Key Metrics — SOPHiA GENETICS